Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-04-26
2011-04-26
Balasubramanian, Venkataraman (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S049000, C514S269000, C544S309000, C544S317000
Reexamination Certificate
active
07932376
ABSTRACT:
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide pyrimidine-based compound, preferably a P2Y12receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and Ia-Ic, or tautomers, salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and Ia-Ic.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt et al.
patent: 4794174 (1988-12-01), Secrist, III
patent: 5049550 (1991-09-01), Zamecnik
patent: 5681823 (1997-10-01), Kim et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 6037343 (2000-03-01), Ali
patent: 6040317 (2000-03-01), Duggan et al.
patent: 6297232 (2001-10-01), Bonnert et al.
patent: 6369064 (2002-04-01), Brown et al.
patent: WO 98/28300 (1998-07-01), None
patent: WO 99/05142 (1999-02-01), None
patent: WO 99/05143 (1999-02-01), None
patent: WO 99/05144 (1999-02-01), None
patent: WO 99/41254 (1999-08-01), None
patent: WO 00/04021 (2000-01-01), None
patent: WO 01/36438 (2001-05-01), None
patent: WO 01/40243 (2001-06-01), None
patent: WO 01/40246 (2001-06-01), None
patent: WO 01/94368 (2001-12-01), None
patent: WO 02/16381 (2002-02-01), None
patent: WO 02/096428 (2002-12-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Tantry et al. Expert. Opin. Pharmacother., 6(12): 2027-2045, 2005.
Rauch et al., Ann. Intern. Med. 134(3): 224-238, 2001.
Van Aken et al., Clin. Appl. Thromb. Hemost., 7(3): 195-204, 2001.
Awaya et al. JP4800579; CA 78: 72530, 1973( CAPLUS Abstract).
Abstracts of Papers, 225THACS National Meeting; New Orleans, LA; Mar. 2003; MEDI-016.
André, et al., “P2Y12regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries,”J. Clin. Invest., 112: 398-406 (2003).
Antiplatelet Trialists' Collaboration, “Collaborative overview of randomized trials of antiplatelet therapy Prevention of death, myocardial antiplatelet therapy in various categories of patients,”Br. Med. J. 308: 81-106 (1994).
Antiplatelet Trialists' Collaboration, “Collaborative overview of randomized trials of antiplatelet therapy—II: Maintenance of vascular antiplatelet therapy,”Br. Med. J. 308: 159-168 (1994).
Baraldi, et al., “NovelN6-(Substituted-phenylcarbamoyl)adenosine-5'-uronamides as Potent Agonists for A3Adenosine Receptors,”Journal of Medicinal Chemistry39(3): 802-806 (1996).
Bennett, et al., “Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel,”N. Engl. J. Med. 342: 1771-1777 (2000).
Bennett, et al., “Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine,”Ann. Intern. Med. 128: 541-544 (1998).
Bernat, et al., “Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat,”Thromb. Haemostas. 70: 812-826 (1993).
Brown, et al., “Matrix Metalloproteinase Inhibitors Containing a (Carboxyalkyl)amino Zinc Ligand: Modification of the P1 and P2' Residues,”J. Med. Chem. 37(5): 674-688 (1994).
Bush, et al., “Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries,”Circulation69: 1161-1170 (1984).
Camaioni, et al., “Adenosine Receptor Agonists: Synthesis and Biological Evaluation of the Diastereoisomers of 2-(3-Hydroxy-3-phenyl-1-propyn-1-yl)NECA,”Bioorganic&Medicinal Chemistry5(12): 2267-2275 (1997).
Cristalli, et al., “2-Aralkynyl and 2-Heteroalkynyl Derivativse of Adenosine-5'-N-ethyluronamide as Selective A2aAdenosine Receptor Agonists,”Journal of Medicinal Chemistry38(9): 1462-1472 (1995).
Dangelmaier, et al., “Potentiation of Thromboxane A2-induced Platelet Secretion by Gi Signaling through the Phosphoinositide-3 Kinase Pathway,”Thromb. Haemostas. 85: 341-348 (2001).
The EPIC investigators; Califf, R.M. coordinating author; “Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein Ilb/Illa Receptor in High-Risk Coronary Angioplasty,”New Engl. J. Med. 330: 956-961 (1994).
Folts, et al., “Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Aspirin,”Circulation54: 365-370 (1976).
Frederick et al., “The Protective Dose of the Potent GPIlb/Illa Antagonist SC-54701A is Reduced When Used in Combination with Aspirin and Heparin in a Canine Model of Coronary Artery Thrombosis,”Circulation93: 129-134 (1996).
Gachet, C., “ADP Receptors of Platelets and their Inhibition,”Thromb. Haemostas. 86: 222-232 (2001).
Geiger, et al., “Specific Impairment of Human Platelet P2YACADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel,”Arterioscler. Thromb. Vasc. Biol. 19: 2007-2011 (1999).
The GUSTO Ila investigators; “Randomized Trial of Intravenous Heparin Versus Recombinant Hirudin for Acute Coronary Syndromes,”Circulation90: 1631-1637 (1994).
Hass, et al., “A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk Patients,”N. Engl. J. Med. 321: 501-507 (1989).
Hechler, of al., “A Role of the Fast ATP-gated P2X1Cation Channel in Thrombosis of Small Arteries In Vivo,”J. Exp. Med. 198: 661-667 (2003).
Herbert, et al., “Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits,”Arterioscl. Thromb. 13: 1171-1179 (1993).
Hourani, et al., “Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate,”Br. J. Pharmacology105: 453-457 (1992).
Humphries et al., “Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo,”Br. J. Pharmacol. 115:1110-1116 (1995).
The IMPACT-II investigators; “Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II,”Lancet349: 1422-1428 (1997).
Ingall, et al., “Antagonists of the Platelet P2TReceptor: A Novel Approach to Antithrombotic Therapy,”J. Med. Chem. 42: 213-220 (1999).
Jacobson, et al., “Structure-Activity Relationships of 9-Alkyladenine and Ribose-Modified Adenosine Derivatives at Rat A3Adenosine Receptors,”Journal of Medicinal Chemistry38(10): 1720-12735 (1995).
Jagroop, et al., “Both the ADP receptors P2Y1and P2Y12, play a roll in controlling shape change in human platelets,”Platelets14: 15-20 (2003).
Kapetanakis, et al., “Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?,”Eur. Heart J. 26:576-83 (2005).
Lee, et al., “N-Alkoxysulfamide,N-Hydroxysulfamide, and Sulfamate Analogues of Methionyl and Isoleucyl Adenylates as Inhibitors of Methionyl-tRNA and Isoleucyl-tRNA Synthetases,” Bioorganic &Medicinal Chemistry Letters13(6): 1087-1092 (2003).
Lekstrom and Bell, “Aspirin in the Prevention of Thrombosis,”Medicine70: 161-177 (1991).
Lyga and Secrist III, “Synthesis of Chain-Extended and C-6' Functionalized Precursors of the Nucleoside Antibiotic Sinefungin,”Journal of Organic Chemistry48(12): 1982-1988 (1983).
Maffrand, et al., “ADP Plays a Key Role in Thrombogenesis in Rats,”Thromb. Haemostas. 59: 225-230 (1988).
McKee, et al., “Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance,”Thromb. Haemostas.
Bednarski Krzysztof
Douglass, III James G.
Shaver Sammy R.
Watson Paul S.
Balasubramanian Venkataraman
Inspire Pharmaceuticals Inc.
Kung Viola T.
Perkins Coie LLP
LandOfFree
Pyrimidine-based non-nucleotide composition and method for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine-based non-nucleotide composition and method for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine-based non-nucleotide composition and method for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2644772